Sparrow Pharmaceuticals, Inc

Sparrow Pharmaceuticals is a targeted cardiometabolic therapeutics company delivering improved outcomes for millions of patients who struggle to control their disease with current options for diabetes and related metabolic conditions. The Company’s lead candidate, clofutriben, is a first-in-class, once-daily, oral HSD-1 inhibitor initially in development for type 2 diabetes with elevated cortisol. HSD-1 inhibition targets an underlying etiology of treatment resistance across the spectrum of metabolic dysfunction and is complementary to leading antidiabetic agents. Sparrow is led by an experienced team of biotech executives, endocrinologists, and drug development veterans with a shared commitment to precision medicine in metabolic disease.